Sex hormones (including androgens, estrogens, etc.) play an important role in human reproduction and sexual function. Androgens and estrogens are important physiological regulators in the development and maintenance of reproductive tissue structure and function. Pathological conditions affecting female genital and urinary tissues have long been believed to be due to estrogen deficiency, but the role of androgens has actually been underappreciated or underestimated.

The company's EG017 belongs to a new Class I chemical drug, and is a new selective androgen receptor modulator. Relevant preclinical research data show that the product has a significant therapeutic effect on improving stress urinary incontinence and dry eye syndrome. According to relevant studies at the cellular and animal levels, EG017 can make up for the deficiency of natural androgens and selectively stimulate tissues with non-androgenic characteristics, but the stimulation of tissues showing androgenic characteristics is relatively weak, thus avoiding the adverse effects of androgens such as female masculinization and reproductive system toxicity. According to the data of Phase IIa studies completed in women with moderate to severe SUI, good results are currently shown, and the company will steadily advance follow-up research. During the reporting period, the Phase II clinical trial of EG017 tablets (selective androgen receptor modulator) for stress urinary incontinence (SUI) and EG017 ointment for dry eye syndrome and other indications has completed the patient enrollment work.